摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(4-氟苯基)-4-哌啶胺 | 164721-12-4

中文名称
1-(4-氟苯基)-4-哌啶胺
中文别名
1-(4-氟苯基)哌啶-4-胺
英文名称
1-(4-fluorophenyl)piperidin-4-amine
英文别名
——
1-(4-氟苯基)-4-哌啶胺化学式
CAS
164721-12-4
化学式
C11H15FN2
mdl
MFCD08059820
分子量
194.252
InChiKey
HLMQCQUHBXFHCK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    310.5±37.0 °C(Predicted)
  • 密度:
    1.119±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.8
  • 重原子数:
    14
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.454
  • 拓扑面积:
    29.3
  • 氢给体数:
    1
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2933399090

SDS

SDS:4374df760e1b07490d2affdde36d82e9
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    1-(4-氟苯基)-4-哌啶胺3,4-二氯-2-甲基吡啶甲醇正庚烷 为溶剂, 以31%的产率得到4-[N-(4-Fluorophenyl)piperidin-4-ylamino]-3-chloro-2-methylpyridine
    参考文献:
    名称:
    Substituted pyridines, their preparation, and their use as pesticides
    摘要:
    该发明涉及以下式的化合物:##STR1## 其中R.sup.1、R.sup.2、R.sup.3和R.sup.4为H、卤素、脂肪基或芳香基,X为O、S或可选择取代的亚胺基,Y为键或可选择取代的二价碳氢基,Z为可选择取代的环烷基或环烯基。该发明还涉及它们的制备过程以及它们作为杀虫剂、螨虫剂和杀菌剂的用途。
    公开号:
    US05723450A1
  • 作为产物:
    描述:
    tert-butyl [1-(4-fluorophenyl)piperidin-4-yl]carbamate盐酸 作用下, 以 1,4-二氧六环 为溶剂, 反应 4.0h, 以49%的产率得到1-(4-氟苯基)-4-哌啶胺
    参考文献:
    名称:
    [EN] INHIBITORS OF DIHYDROCERAMIDE DESATURASE FOR TREATING DISEASE
    [FR] INHIBITEURS DE LA DIHYDROCÉRAMIDE DÉSATURASE POUR LE TRAITEMENT D'UNE MALADIE
    摘要:
    本文披露了二氢神经酰胺脱饱和酶1(Des1)抑制剂化合物和组合物,这些化合物和组合物在治疗疾病方面非常有用,例如代谢紊乱,预期通过抑制Des1对患者具有治疗作用。还提供了在人类或动物受试者中抑制Des1活性的方法。
    公开号:
    WO2019140188A1
点击查看最新优质反应信息

文献信息

  • Triazinone compound and T-type calcium channel inhibitor
    申请人:NISSAN CHEMICAL INDUSTRIES, LTD.
    公开号:US09403798B2
    公开(公告)日:2016-08-02
    There is provided a novel triazinone compound that has an excellent T-type voltage-dependent calcium channel inhibitory activity and is specifically useful for treatment of pain. A compound of Formula (I), a tautomer of the compound, a pharmaceutically acceptable salt thereof, or a solvate thereof: where each substituent is defined in detail in the description or claims, for example R1 is H or C1-6 alkoxy, etc., each of L1 and L2 is independently a single bond or NR2, etc., L3 is C1-6 alkylene, etc., A is C6-14 aryl or 5 to 10-membered heteroaryl which is optionally substituted, etc., B is C3-11 cycloalkylene, etc., D is C6-14 aryl or 5 to 10-membered heteroaryl which is optionally substituted, etc.
    提供了一种新型的三嗪酮化合物,该化合物具有优良的T型电压依赖性钙通道抑制活性,特别适用于治疗疼痛。公式(I)的化合物、该化合物的tautomer、药用可接受的盐或溶剂: 其中,每个取代基在说明或权利要求中有详细定义,例如,R1是H或C1-6烷氧基等,L1和L2各自独立为单键或NR2等,L3为C1-6亚烷基等,A为C6-14芳基或5至10元杂芳基,该芳基可被选配地取代等,B为C3-11环烷基等,D为C6-14芳基或5至10元杂芳基,该芳基可被选配地取代等。
  • [EN] CB1 MODULATOR COMPOUNDS<br/>[FR] COMPOSES MODULATEURS DE CB1
    申请人:LILLY CO ELI
    公开号:WO2005066126A1
    公开(公告)日:2005-07-21
    Novel compounds of structural formula (I) are disclosed. As modulators of the Cannabinoid-1 (CB1) receptor, these compounds are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. As such, compounds of the present invention are useful as in the treatment, prevention and suppression of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders (e.g., multiple sclerosis, Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis), cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine. The compounds are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith.
    结构式(I)的新化合物已被披露。作为大麻素-1(CB1)受体的调节剂,这些化合物在治疗、预防和抑制由CB1受体介导的疾病方面是有用的。因此,本发明的化合物在治疗、预防和抑制精神病、记忆缺陷、认知障碍、偏头痛、神经病、神经炎性疾病(例如多发性硬化症、吉兰-巴雷综合征和病毒性脑炎的炎症后遗症)、脑血管意外、头部创伤、焦虑症、压力、癫痫、帕金森病和精神分裂症方面是有用的。这些化合物还可用于治疗物质滥用障碍,特别是对阿片类药物、酒精和尼古丁的治疗。这些化合物还可用于治疗与过度食物摄入及相关并发症相关的肥胖症或进食障碍。
  • [EN] PYRIDINEDIONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE<br/>[FR] PYRIDINEDIONE CARBOXAMIDES CONVENANT COMME INHIBITEURS DE LA LIPASE ENDOTHÉLIALE
    申请人:BRISTOL MYERS SQUIBB CO
    公开号:WO2013049104A1
    公开(公告)日:2013-04-04
    The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are endothelial lipase inhibitors which may be used as medicaments.
    本发明提供了如下式(I)的化合物:如规范中定义的以及包含任何这种新化合物的组合物。这些化合物是内皮酯酶抑制剂,可用作药物。
  • 5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF
    申请人:Samumed, LLC
    公开号:US20190263821A1
    公开(公告)日:2019-08-29
    Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, Darier's disease, scleroderma, cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.
    披露了用于治疗各种疾病和病理的吲唑化合物。更具体地说,本公开涉及使用吲唑化合物或其类似物来治疗由Wnt途径信号激活所特征的疾病(例如肌腱病、皮炎、牛皮癣、硬皮病、鱼鳞病、雷诺综合症、达里氏病、硬皮病、癌症、异常细胞增殖、血管生成、阿尔茨海默病、肺病和骨关节炎),以及通过Wnt途径信号介导的细胞事件的调节,以及与DYRK1A过度表达相关的神经病理状况/疾病。
  • Fluoropyrrolidines as dipeptidyl peptidase inhibitors
    申请人:——
    公开号:US20040242636A1
    公开(公告)日:2004-12-02
    The present invention relates to novel compounds, their use for inhibiting post prolin/analine-cleaving proteases, such as serine proteases, such as dipeptidyl peptidases, such as dipeptidyl peptidase IV (DPP-IV), and to methods for their production and their therapeutic utility.
    本发明涉及新颖化合物,其用于抑制后脯氨酸/苯丙氨酸剪切蛋白酶,例如丝氨酸蛋白酶,例如二肽基肽酶,例如二肽基肽酶IV(DPP-IV),以及其生产方法和治疗效用。
查看更多